LONDON (ShareCast) - (Sharecast News) - Clinical-stage biotechnology company Destiny Pharma noted the launch of a series of videos and explainer documents from the UK BioIndustry Association (BIA) celebrating UK bioscience and revealing the research and development taking place in biotech companies around the UK on Friday.
The AIM-traded firm said it had been chosen, alongside selected other UK biotech companies, to exemplify the UK's status in key areas of biotechnology including antimicrobial resistance, genomics, cell and gene therapy and engineering biology.

It said the videos and explainers covered strategic technologies being developed to offer potentially life-changing solutions to individuals and societies across the globe.

"We welcome the BIA's continued support for companies investing in the development of much needed novel anti-infective treatments," said Destiny's founder and chief scientific officer Dr William Love.

"The UK is one of the global leaders in antimicrobial resistance research and these materials give a true sense of the ground-breaking work being done here.

"Destiny Pharma is well-positioned to address in part this global issue through the continued clinical development of our novel XF drug platform."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE